Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBP
Corbus Pharmaceuticals — Investor Presentation (September 2018)
44 slides from Corbus Pharmaceuticals's investor presentation, Sep 20, 2018
Slide 1: Vision: Become the Leader in Treatment of Inflammatory and Fibrotic Diseases
Vision: Become the Leader in the Treatment of Inflammatory and Fibrotic Diseases by Targeting the Endocannabinoid System with the Industry's Leading Pipeline
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains certain forward-looking statements, including those relating to the Company's product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, bus
Slide 3: Vision
VISION Become the Leader in the Treatment of Inflammatory and Fibrotic Diseases by Targeting the Endocannabinoid System with the Industry's Leading Pipeline
Slide 4: Investment Highlights
Investment Highlights NASDAQ: CRBP Founded: 2014 Employees: 65 Based in: Norwood, MA Capital raised to-date: $128 million Additional awards and grants from NIH and CFF: $45 million Leading ECS Pipeline Rationally-designed small molecules e ~ hill °5 billion Potential Annual Market Opportunity! REREE
Slide 5: Focus on the Endocannabinoid System (ECS)
Focus on the Endocannabinoid System (ECS) The ECS is a master-regulator of inflammation and fibrosis Broad applicability Well-understood biology
Slide 6: ECS as a Therapeutic Target
Promising Pipeline ECS as a Therapeutic Target » Major receptors: CB2 and CB1 * GPCRs that modulate cAMP, intracellular signaling pathways, and ion channels * CB2 human * CB1 human polymorphisms: polymorphisms: autoimmunity * inflammation ‘inflammation # fibrosis in NASH fibrosis or PBC = Confirmed
Slide 7: Corbus Is Evolving
Corbus Is Evolving CORBUS YESTERDAY! CORBUS TODAY Industry's 1** use of ECS receptor (CB2) Second ECS-targeting drug candidate agonist as potential treatment for patients headed for clinical testing 2019 + with rare inflammatory and fibrotic diseases robust pre-clinical pipeline ne CB2 activator in
Slide 8: Two Differentiated Drug Candidates Selectively Targeting ECS
Two Differentiated Drug Candidates Selectively Promising Pipeline Targeting ECS to Treat Inflammation/Fibrosis Receptor Blood Brain Barrier compound Affinity Penetration Phase 3 in SSc & DM, CBI-CB2 Lenabasum positive Phase 2 data CB2 agonist 112 Limited in 3 indications . Preparing for Phase 1 to b
Slide 9: Early and Late Stage Programs
Early and Late Stage Programs Preclinical Systemic Sclerosis Lenabasum Dermatomyositis Systemic Lupus Erythematosus Phase 1 CRB-4001 Pre-clinical library (over 600 compounds) Targeting 2019 Phase 2 Phase 3 Promising Pipeline Launch Targeting 2021
Slide 10: History of "Pipeline in a Product" for Successful Drugs
History of “Pipeline in a Product” for Successful Drugs Targeting Inflam 4 of top 5 top-selling US drugs (2016) with combined sales of $42 billion in 2017'” Rituxan Rituximab Enbrel etanercept mation @)Remicade INFLIXIMAB, Significant Market Opportunity HUMIRA’ adalimumab 2017 WW sales? 2017 WW sale
Slide 11: Significant Market Opportunity
Significant Market Opportunity Broad Applicability of Expanded Corbus Pipeline Lenabasum Preferential CB2 agonist Peripheral preference TARGETED INDICATIONS + Systemic Sclerosis (Phase 3) +» Dermatomyositis (Phase 3) + Lupus (Phase 2) + Cystic Fibrosis (Phase 2) Projected Launch 2021 CRB-4001 2nd Ge
Slide 12: Significant Market Opportunity for Lead Program
Significant Market Opportunity for Lead Program Significant Market Opportunity ~200,000 patients in U.S., £ ~80,000 patients in U.S., EU and Japan’ ~70,000 patients in U.S. and EU CRB-4001 é EU and Japan‘ rx Be © ~$1.4B- $2.2B te “= | enabasum annual ae potential a market opportunity’ © ~$1B-$2B Len
Slide 13: Unencumbered Commercial Rights Provide Significant Market Opportunity
Unencumbered Commercial Rights Provide Stanficant Market Opportinlty for Global / Regional Strategic Optionality NORTH AMERICA SSc: 84,000 DM: 40,000 SLE: 280,000 CF: 30,000 PATIENT POPULATIONS": EUROPE PATIENT POPULATIONS": S$Sc: 81,000 JAPAN PATIENT Hee POPULATIONS": SLE: 240,000 ; CF: 39,000 $Sc:
Slide 14: Competitive Landscape
Competitive Landscape \NNABINOID approved 2018 Insys: Syndros™ (THC) approved 2017 Systemic Sclerosis + Roche (Tocilizumab IL-6 receptor blocker: Ph 3 missed primary outcome) + Bayer (Riociguat, PAH drug: Ph 2 missed primary outcome) + BI (Nintedanib, IPF drug: Ongoing Ph 3 for ILD in SSc) + BMS (Ab
Slide 15: Lenabasum
15 Lenabasum Leadership in Targeting ECS for Rare Inflammatory and Fibrotic Diseases
Slide 16: Lenabasum At A Glance
Lenabasum Lenabasum At A Glance @& Orally-administered, rationally-designed, preferential CB2 agonist @ Active in animal models including systemic sclerosis, CF and rheumatoid arthritis @ Active in human model of innate immune response (“blister model”) @ Non-immunosuppressive with favorable safety
Slide 17: Lenabasum In Vitro Profiling Suggests Advantages Over Commercial Anti-Inflammatories
Lenabasum /n Vitro Profiling Suggests oe Advantages Over Commercial Anti-Inflammatories IMMUNOSUPPRESSION EPITHELIAL INFLAMMATION FIBROSIS | a Lenabasum is not Lenabasum reduces production Lenabasum reduces production of eS = suppressing immune of inflammatory mediators by _inflammatory mediators an
Slide 18: Biologic Activity of Lenabasum in Patients with Targeted Diseases
Lenabasum Biologic Activity of Lenabasum in Patients with Targeted Diseases Dermatomyositis Cystic Fibrosis Co-localization of CD4, CB2, IFNy staining in skin Reduction in inflammatory markers in lung sputum eduction with lenabasum 20 mg BID compared to placebo (Log) Decrease in CD4 TT cells and Typ
Slide 19: Lenabasum Safety Overview
Lenabasum Lenabasum Safety Overview * No serious or severe lenabasum-related AEs to-date * Maximum Tolerated Dose: 180 mg total daily dose. - Dose limiting toxicity = Multiple mild to moderate AEs occurred in a given subject, e.g., dizziness, fatigue, nausea, vomiting, feeling odd, and orthostatic h
Slide 20: Systemic Sclerosis (SSc) Program Overview
Lenabasum Systemic Sclerosis (SSc) Program Overview Our most advanced program with potential commercialization in 2021 © seeeeeaesaueaueaeecesursnseneeess(@) sa suemaemeagaeacoaeeenesmasseess(@) Positive Phase 2 Ongoing open-label Ongoing Phase 3 results extension: 52 weeks+ RESOLVE-1 study with (lo
Slide 21: Systemic Sclerosis Overview
. : : Lenabasum Systemic Sclerosis Overview Rare and life-threatening autoimmune disease characterized by tissue inflammation and fibrosis | ~$1.4B - ~200,000 40-60% gj Zero $2.28 people with SSc in mortality in a SSc-specific annual potential US, EU and Japan’ 10 years? drugs approved market opport
Slide 22: SSc At A Glance
SSc At A Glance + Images (top) Provided by the Scleroderma Foundation Lenabasum Sclero = stone, Derma = skin Mortality: Most lethal of the systemic autoimmune diseases, 40-60% 10-year survival with more severe disease Pathogen Autoimmune disease with chronic activation of innate immune responses; or
Slide 23: mRSS: Clinically Important Difference Achieved in Skin in Phase 2 Study
Lenabasum mRSS: Clinically Important Difference Achieved in Skin in Phase 2 Study Primary efficacy outcome for Ph 3 -4 to -5 points is generally considered MCID' Mean time off drug before start of OLE = 20 wks Stable standard-of-care drugs, including immunosuppressive drugs OLE Lenabasum r i Compara
Slide 24: ACR CRISS Score: Clear Improvement Achieved in Phase 2
c re) 3 @ £ 2 3 8 a n a = oO Overall Disease Stable standard-of-care drugs, including immunosuppressive drugs DBPC. OLE Lenabasum 100% =O Lenabasum | —@- Placebo === Continued standard-of-care only a 3 & 888s RRs Placebo range N= 4 other studies 0 4 8 1216 0 4 8 1216 20 24 28 32 36 40 44 48 52 Weeks
Slide 25: Distribution of CRISS Scores and Change in mRSS at Week 52 OLE
Lenabasum Distribution of CRISS Scores and Change in mRSS at Week 52 OLE CHANGE IN mRSS CRISS Scores 5 100% I 90% oe | | 80% 5 70% n 60% a 7 “10 s 50% “15 fe 40% 30% 20 20% 25 10% il Individual Subjects m% : Individual Subjects 77% of subjects had 2 5 50% of subjects achieved point reduction in mRSS
Slide 26: Ongoing Phase 3 RESOLVE-1 Study
Ongoing Phase 3 RESOLVE-1 Study Lenabasum Topline data expected 2020 Double-blind, randomized, placebo-controlled study 20mg BID 5mg BID Placebo Week study Multinational ~354 subjects 1:1:1 dosing Primary Endpoint: Change from baseline in mRSS Secondary Endpoints: Change from baseline in HAQ-DI; ACR
Slide 27: Dermatomyositis (DM) Program Overview
Lenabasum Dermatomyositis (DM) Program Overview Second rare autoimmune disease with positive Phase 2 clinical data Qetrttteteneeeeeenecssncreeeennes @sseseseeee cae eeeaesmaemenseseses@) Phase 2 results Ongoing open-label Phase 3 study expected funded by NIH extension: 52 to commence end grant weeks
Slide 28: DM Overview
Lenabasum DM Overview Rare and serious autoimmune condition related to SSc and characterized by skin and muscle inflammation ~80,000 30% i Zero ~$1B - $2B people with DM in mortality in f#]DM-specific ©, ues Paver US, EU and Japan! 5 years? “drugs approved Sts Aaa for lenabasum 1: Heatth Advances, L
Slide 29: Dermatomyositis At A Glance
Lenabasum Dermato = skin, Myositis = muscle inflammation Autoimmune disease with organ inflammation, fibrosis, atrophy and vascular changes Proximal weakness, rash, pain, itch, shortness of breath Immunosuppressives with significant toxicity sieges Qin)
Slide 30: CDASI Activity Score - Clinically Meaningful Improvement in Skin
CDASI Activity Score - Demonstrated Clinically Lenabasum Meaningful Improvement in Skin , Stable standard-of-care drugs, including immunosuppressive drugs . Cutaneous Dermatomyositis ee ae wez0 weeks 0-20 Disease Activity and Severity Re 2 entetieg OLE: N= 17 completed Week 28 at data cut Index (CDA
Slide 31: Upcoming Phase 3 Clinical Study Design
Lenabasum Upcoming Phase 3 Clinical Study Design Study expected to commence end of 2018 Double-blind, randomized, placebo-controlled study 20mg BID 5mg BID Placebo Week study Multinational ~150 subjects 2:1:2 dosing Primary Endpoint: American College of Rheumatology (ACR) / European League Against R
Slide 32: Cystic Fibrosis (CF) Program Overview
Lenabasum Cystic Fibrosis (CF) Program Overview Targeting all patients while not competing with CFTR therapies Positive Phase Ongoing Large Phase 2a results 2b study FDA Orphan Drug = $30M in development Awards Fast Track FDA ‘s i) EUROPEAN MEDICINES AGINCY Designation from the Cystic Fibrosis Found
Slide 33: CF At A Glance
CF At A Glance Lenabasum Genetic disease characterized by chronic lung inflammation that leads to lung damage and fibrosis Inflammation _,_.; Sane em Zero ~$0.7 - $1B ~70,000 and fibrosis 3 § $' dl drugs approved annual potential people with CF in play key role in wal i s i 7 major markets! morbidit
Slide 34: Lenabasum Reduced PEx in Completed Phase 2 Study
Phase 2 Study Lenabasum Reduced PEx in Completed Lenabasum Primary outcome for ongoing Phase 2b study Rate of Pulmonary Exacerbations Requiring New Antibiotics Weeks 1-4 Weeks 5-12 4 1 g 09 09 3 os 08 Saree 077 o7 § os os Boos a 3 04 ire 0.46 Bos oss 2 o2 02 Bas if 0 : 0 Placebo 5mg Placebo 20mg 20m
Slide 35: Ongoing CF Phase 2b Study
Lenabasum Ongoing CF Phase 2b Study Open to people with CF 12 years and older, regardless of mutation or current background medications, including Orkambi®, Kalydeco® and Symdeko® Double-blind, randomized, placebo-controlled study 20mg BID 5mg BID Placebo Week study Multinational ~415 subjects 2:1:2
Slide 36: Jenrin Transaction
36 Jenrin Transaction Accelerates Leadership in ECS for Targeting Inflammation and Fibrosis Beyond Rare Diseases
Slide 37: About Jenrin Discovery
CRB-4001 About Jenrin Discovery + Privately-held, Chadds Ford, PA-based drug discovery company * Focused on ECS-based therapies for liver disease, diabetes and obesity en rina + First-in-class small molecule drug candidates designed to selectively target peripheral tissues [Discovery Lead program =
Slide 38: CRB-4001: Targeting Peripheral Organ Fibrosis with Strong Preclinical Data
CRB-4001 ng/mL or ng/g 3 CRB-4001: Targeting Peripheral Organ Fibrosis with Strong Pr: Clinical Data CRB-4001 | | Targeting organ fibrosis Preparing for Phase 1 in the periphery in 2019 Exposure limited to the periphery (28-day dosing at 3 mg/kg/day in wild-type mice) Plasma Brain Levels AUC radioac
Slide 39: CRB-4001 As a Potential Treatment of NASH
Treatment of NASH Lead Compound, CRB-4001, As a Potential CRB-4001 CRB-4001 Blocks Metabolic Abnormalities and Reduces Biomarkers of Liver Damage in NASH Model & 5,0 HD Bae HD $ = Fi a 4 i {: $2 2” : 8 10 | 7 a a Ven Ven CrBO0% 200, 200) 52. ua 10) = 10 re 2 2 i > 100 2 10 2 2 5 0 0 Veh Veh CRB4OOT
Slide 40: Potential Applicability of CRB-4001 to Other Diseases
Potential Applicability of CRB-4001 to Other Diseases LUNG FIBROSIS: Normalization of genes associated with active fibrogenesis in a mouse model of radiation-induced pulmonary fibrosis 5 Collagen «2 type | . SMA. 7{mce,* os mce,** . a ee § [BE C8") conmnar ips bs ea Bo g5! * $39 33 # gee ge 1 ° ° on
Slide 41: Management Team and Board with Proven Record of Execution
Corporate Overview Management Team and Board with Proven Record of Execution Management Team Board of Directors Yuval Cohen, PhD ‘Amb. Alan Holmer Ret.- Chairman of the Board Chief Executive Officer, Director Chairman of the Board More than 13 years of executive leadership experience in inflammatory
Slide 42: Financial Profile: CRBP (NASDAQ)
Corporate Overview Financial Profile: CRBP (NASDAQ) - $128M equity raised to-date - $45M non-dilutive funding from NIH and CF Foundation’ 57.2M ~$65M : $296M Common shares outstanding * Cash balance? i Market Cap* (68.9M fully diluted)? £ x ‘YX 1: Includes development award from CFF announced in Jan
Slide 43: Investment Highlights
Investment Highlights NASDAQ: CRBP Founded: 2014 Employees: 65 Based in: Norwood, MA Capital raised to-date: $128 million Additional awards and grants from NIH and CFF: $45 million Leading ECS Pipeline Rationally-designed small molecules e ~ hill °5 billion Potential Annual Market Opportunity! REREE
Slide 44: Become the Leader in Treatment of Inflammatory and Fibrotic Diseases
> Become the Leader in Treatment of CO R B US Inflammatory and Fibrotic Diseases by RiARMACEUTICALS Targeting the Endocannabinoid System with the Industry’s Leading Pipeline Corbus Pharmaceutical Holdings, Inc. 617.963.0100 info@corbuspharma.com
Corbus Pharmaceuticals Holdings — Investor Presentation (September 2018) on 6ix